We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+34.12%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$73.8M
AUM Growth
+$28.4M
Cap. Flow
+$17.1M
Cap. Flow %
23.17%
Top 10 Hldgs %
55.69%
Holding
77
New
37
Increased
5
Reduced
25
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$1.64M
2
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.49M
3
IMMU
Immunomedics Inc
IMMU
+$1.01M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$713K
5
INSM icon
Insmed
INSM
+$698K

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$870K
2
BIIB icon
Biogen
BIIB
+$320K
3
EXEL icon
Exelixis
EXEL
+$233K
4
IONS icon
Ionis Pharmaceuticals
IONS
+$141K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$130K

Sector Composition

Rank Sector Weight
1 Healthcare 57.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
26
DELISTED
Epizyme, Inc
EPZM
$624K 0.85%
+50,378
New +$563K
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$619K 0.84%
+3,674
New +$547K
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$559K 0.76%
+10,852
New +$469K
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$543K 0.74%
+6,780
New +$501K
MGNX icon
30
MacroGenics
MGNX
$280M
$541K 0.73%
+30,075
New +$520K
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$535K 0.73%
+9,725
New +$463K
EXAS
32
DELISTED
Exact Sciences
EXAS
$528K 0.72%
+6,093
New +$519K
RGNX icon
33
Regenxbio
RGNX
$565M
$506K 0.69%
+8,832
New +$438K
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$502K 0.68%
+9,479
New +$466K
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$500K 0.68%
+36,731
New +$449K
NTLA icon
36
Intellia Therapeutics
NTLA
$1.56B
$487K 0.66%
+28,490
New +$425K
VKTX icon
37
Viking Therapeutics
VKTX
$4.32B
$482K 0.65%
+48,485
New +$406K
CRSP icon
38
CRISPR Therapeutics
CRSP
$4.7B
$472K 0.64%
+13,214
New +$457K
ANAB icon
39
AnaptysBio
ANAB
$1.6B
$447K 0.61%
+6,116
New +$422K
MDGL icon
40
Madrigal Pharmaceuticals
MDGL
$12.5B
$447K 0.61%
+3,570
New +$444K
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
$438K 0.59%
+9,770
New +$448K
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$432K 0.59%
+18,631
New +$488K
PCRX icon
43
Pacira BioSciences
PCRX
$1.01B
$428K 0.58%
11,250
– –
FBIO icon
44
Fortress Biotech
FBIO
$115M
$417K 0.57%
15,602
– –
CLLS
45
Cellectis
CLLS
$262M
$409K 0.55%
+22,309
New +$395K
SUPN icon
46
Supernus Pharmaceuticals
SUPN
$2.78B
$408K 0.55%
+11,648
New +$433K
RUBY
47
DELISTED
Rubius Therapeutics, Inc
RUBY
$391K 0.53%
+21,610
New +$332K
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.82B
$388K 0.53%
+3,252
New +$418K
WVE icon
49
Wave Life Sciences
WVE
$1.11B
$377K 0.51%
+9,716
New +$394K
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.89B
$351K 0.48%
5,064
-275
-5% -$15.7K
1
2
3 4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opus Point Partners Management held 77 positions worth $73.8M, up 62% from $45.4M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $17.1M of net new capital in Q1 2019, opening 37 new positions and adding to 5 existing holdings. Its largest new stake was Bristol-Myers Squibb: 33,000 shares worth $1.57M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 50% a quarter earlier.

On the sell side, the largest reduction was Exelixis, an estimated $233K trimmed.

  • Opus Point Partners Management's largest Q1 2019 buy was Bristol-Myers Squibb: 33,000 shares worth $1.57M.
  • Opus Point Partners Management added most to Direxion Daily S&P Biotech Bull 3X ETF in Q1 2019, an estimated $1.49M increase.
  • Opus Point Partners Management's biggest Q1 2019 reduction was Exelixis, cutting an estimated $233K.
  • Opus Point Partners Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $870K.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $73.8M portfolio in Q1 2019.
  • Opus Point Partners Management opened 37 new positions and closed 2 in Q1 2019.
  • Opus Point Partners Management's portfolio value rose 62% quarter-over-quarter to $73.8M.

Based on Opus Point Partners Management's 13F filing for Q1 2019, filed 15 May 2019.